Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Rukmini Govekar"'
Publikováno v:
Journal of Translational Medicine, Vol 17, Iss 1, Pp 1-15 (2019)
Abstract Background SWATH-MS has emerged as the strategy of choice for biomarker discovery due to the proteome coverage achieved in acquisition and provision to re-interrogate the data. However, in quantitative analysis using SWATH, each sample from
Externí odkaz:
https://doaj.org/article/45a978607b3040319691eea236b03662
Autor:
Rahul Mojidra, Arti Hole, Keita Iwasaki, Hemanth Noothalapati, Tatsuyuki Yamamoto, Murali Krishna C, Rukmini Govekar
Publikováno v:
Cells, Vol 10, Iss 10, p 2506 (2021)
Monitoring the development of resistance to the tyrosine kinase inhibitor (TKI) imatinib in chronic myeloid leukemia (CML) patients in the initial chronic phase (CP) is crucial for limiting the progression of unresponsive patients to terminal phase o
Externí odkaz:
https://doaj.org/article/b5200081c3024832a4b2d75d568019ee
Publikováno v:
Anemia, Vol 2012 (2012)
In pathological conditions with concurrent neutrophilia, modifications of erythrocyte membrane proteins are reported. In chronic myeloid leukemia (CML), a myeloproliferative disease wherein neutrophilia is accompanied by enhanced erythrophagocytosis,
Externí odkaz:
https://doaj.org/article/83d38186d80e4f1cb0d0f588dc7268fb
Autor:
Priyanka A. Jadhav, Kshama Pansare, Arti Hole, Arvind Ingle, Rukmini Govekar, C. Murali Krishna
Publikováno v:
Journal of Raman Spectroscopy. 54:37-46
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::34deafacd04f25c225f6e4e595fa2852
https://doi.org/10.1002/jrs.6450
https://doi.org/10.1002/jrs.6450
Autor:
Rukmini Govekar
Publikováno v:
Biomedical Journal of Scientific & Technical Research. 43
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b7ad559287228e76e82958c157068c55
https://doi.org/10.26717/bjstr.2022.43.006944
https://doi.org/10.26717/bjstr.2022.43.006944
Autor:
Vaishnavi Khamkar, Sarika Tilwani, Dhanlaxmi Shetty, Mythreyi Narasimhan, Sorab N. Dalal, Sanjay Gupta, Rukmini Govekar, Papagudi Ganesan Subramanian
Publikováno v:
J Cell Commun Signal
Chronic myeloid leukemia (CML) epitomises successful targeted therapy, where inhibition of tyrosine kinase activity of oncoprotein Bcr-Abl1 by imatinib, induces remission in 86% patients in initial chronic phase (CP). However, in acute phase of blast
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::035b3f1e3c19ed9252bb79c50cc23173
https://europepmc.org/articles/PMC8891420/
https://europepmc.org/articles/PMC8891420/
Additional file 1. Dendrograms representing hierarchical clustering of control and test groups based on differentiators obtained by p-value, fold change or both in both datasets.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::956f735d1b71da74f7fb572544568233
Autor:
Sushmita Jha, Shalini Singh, Shivanjali Saxena, Nidhi Sharma, Ishan Agrawal, Rukmini Govekar, Pranali Panchal, Epari Sridhar, Tejpal Gupta
Publikováno v:
The Journal of Immunology. 206:109.10-109.10
Gliomas are the most prevalent primary brain tumors with immense clinical heterogeneity, poor prognosis and survival. Gliomas arise from glial cells and are heavily infiltrated with innate immune cells. In India high-grade gliomas or Glioblastomas (G
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f74c98ddb983389b9cad917a7779dd3a
https://doi.org/10.4049/jimmunol.206.supp.109.10
https://doi.org/10.4049/jimmunol.206.supp.109.10